Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | FOS | P01100 | 1/20 | 0.42 |
| ▸ | TTR | P02766 | 1/20 | 0.42 |
| ▸ | JUN | P05412 | 1/20 | 0.42 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.42 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.42 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | LDHA | P00338 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11419411 | 0.84 | LDHA (0.57) | CYP3A4FOSTTRJUNNR3C1 | |
| SCHEMBL1048622 | 0.81 | FOS (0.44) | MMP1CYP3A4FOSTTRJUN | |
| SCHEMBL8180097 | 0.81 | FOS (0.50) | MMP1CYP3A4FOSTTRJUN | |
| SCHEMBL4432280 | 0.81 | MMP1 (0.53) | MMP1CYP3A4FOSTTRJUN | |
| SCHEMBL1083505 | 0.80 | HTR2A (0.45) | FOSTTRJUNNR3C1HSD17B1 | |
| SCHEMBL1048328 | 0.80 | PNMT (0.46) | MMP1CYP3A4FOSTTRJUN | |
| SCHEMBL1067852 | 0.80 | HTR1A (0.45) | MMP1CYP3A4FOSTTRJUN | |
| SCHEMBL14655562 | 0.80 | MBOAT4 (0.41) | MMP1CYP3A4FOSTTRJUN | |
| SCHEMBL1047457 | 0.79 | TAAR1 (0.50) | FOSTTRJUNNR3C1HSD17B1 | |
| SCHEMBL27835674 | 0.78 | FOS (0.51) | MMP1CYP3A4FOSTTRJUN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4547250-A1 | METHODS AND COMPOSITIONS RELATING TO CONTROLLING PSYCHEDELIC EFFECTS WITH SEROTONIN RECEPTOR MODULATORS | Terran Biosciences Inc. (US) | 2025-05-07 | — | — | EP | claimed |
| US-20240197681-A1 | METHODS AND COMPOSITIONS RELATING TO PSYCHEDELICS AND SEROTONIN RECEPTOR MODULATORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-06-20 | — | — | US | claimed |
| EP-4313030-A1 | METHODS AND COMPOSITIONS RELATING TO PSYCHEDELICS AND SEROTONIN RECEPTOR MODULATORS | Terran Biosciences, Inc. (US) | 2024-02-07 | — | — | EP | claimed |
| WO-2024006984-A1 | METHODS AND COMPOSITIONS RELATING TO CONTROLLING PSYCHEDELIC EFFECTS WITH SEROTONIN RECEPTOR MODULATORS | TERRAN BIOSCIENCES INC. (US) | 2024-01-04 | — | — | WO | claimed |
| EP-2884962-B1 | PREPARATION OF DESICCATED LIPOSOMES FOR USE IN COMPRESSIBLE DELIVERY SYSTEMS | SMARTEK INT LLC (US) | 2019-05-01 | — | — | EP | claimed |
| US-20150216799-A1 | PREPARATION OF DESICCATED LIPOSOMES FOR USE IN COMPRESSIBLE DELIVERY SYSTEMS | SMARTEK INTERNATIONAL LLC | 2015-08-06 | — | — | US | claimed |
| EP-2884962-A2 | PREPARATION OF DESICCATED LIPOSOMES FOR USE IN COMPRESSIBLE DELIVERY SYSTEMS | Smartek International LLC (US) | 2015-06-24 | — | — | EP | claimed |
| WO-2014028796-A2 | PREPARATION OF DESICCATED LIPOSOMES FOR USE IN COMPRESSIBLE DELIVERY SYSTEMS | SMARTEK INTERNATIONAL LLC (US) | 2014-02-20 | — | — | WO | claimed |
| US-12599578-B2 | Compositions comprising enzyme-cleavable prodrugs and controlled release nafamostat and methods of use thereof | Ensysce Biosciences Inc. (US) | 2026-04-14 | — | — | US | disclosed |
| EP-4673430-A2 | PHENYLALKYLAMINE PRODRUGS | Alexander Shulgin Research Institute, Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| EP-4673127-A1 | DEUTERATED AND FLUORINATED EMPATHOGENS | Alexander Shulgin Research Institute, Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| US-20250388529-A1 | N-Substituted Phenylalkylamines and Their Use as Therapeutic Agents | ALEXANDER SHULGIN RES INSTITUTE INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-12465578-B2 | Substituted alpha-ethyl phenylalkylamines | ALEXANDER SHULGIN RESEARCH INSTITUTE, INC. (US) | 2025-11-11 | — | — | US | disclosed |
| EP-4618981-A1 | COMBINATIONS OF MONOAMINE OXIDASE INHIBITORS AND SEROTONIN RECEPTOR AGONISTS AND THEIR THERAPEUTIC USE | Remedi, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| US-8017050-B2 | Water purification membranes with improved fouling resistance | BOARD OF REGENTS THE UNIVERSITY OF TEXAS SYSTEM (US) | 2011-09-13 | — | — | US | disclosed |
| EP-2318126-A2 | WATER PURIFICATION MEMBRANES WITH IMPROVED FOULING RESISTANCE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2011-05-11 | — | — | EP | disclosed |
| WO-2011005258-A1 | POLYMER DEPOSITION AND MODIFICATION OF MEMBRANES FOR FOULING RESISTANCE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2011-01-13 | — | — | WO | disclosed |
| US-20100059433-A1 | POLYMER DEPOSITION AND MODIFICATION OF MEMBRANES FOR FOULING RESISTANCE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2010-03-11 | — | — | US | disclosed |
| US-20100051538-A1 | WATER PURIFICATION MEMBRANES WITH IMPROVED FOULING RESISTANCE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2010-03-04 | — | — | US | disclosed |
| WO-2010006196-A2 | WATER PURIFICATION MEMBRANES WITH IMPROVED FOULING RESISTANCE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2010-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388529-A1 | N-Substituted Phenylalkylamines and Their Use as Therapeutic Agents | CNR2, CNR1, HCN3 | MMP1 3353/4885CYP3A4 994/4885FOS 1575/4885 |
| US-12465578-B2 | Substituted alpha-ethyl phenylalkylamines | PNMT, SLC18A2, SLC1A2 | MMP1 4155/4885CYP3A4 1057/4885FOS 4811/4885 |
| US-20240197681-A1 | METHODS AND COMPOSITIONS RELATING TO PSYCHEDELICS AND SEROTONIN RECEPTOR MODULATORS | HTR1A, HTR2A, HTR3A | MMP1 4720/4885CYP3A4 2453/4885FOS 1847/4885 |
| US-12599578-B2 | Compositions comprising enzyme-cleavable prodrugs and controlled release nafamostat and methods of use thereof | OPRK1, OPRL1, OPRM1 | MMP1 82/4885CYP3A4 45/4885FOS 831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.